Exagen (NASDAQ:XGN – Get Rating) and MedTech Acquisition (NASDAQ:MTAC – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.
Profitability
This table compares Exagen and MedTech Acquisition’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Exagen | -90.98% | -79.22% | -41.83% |
| MedTech Acquisition | N/A | -17.92% | 1.66% |
Earnings & Valuation
This table compares Exagen and MedTech Acquisition’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Exagen | $45.56 million | 1.15 | -$47.39 million | ($2.52) | -1.23 |
| MedTech Acquisition | N/A | N/A | $5.54 million | N/A | N/A |
Institutional and Insider Ownership
40.6% of Exagen shares are owned by institutional investors. Comparatively, 21.0% of MedTech Acquisition shares are owned by institutional investors. 36.8% of Exagen shares are owned by company insiders. Comparatively, 76.2% of MedTech Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Volatility & Risk
Exagen has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, MedTech Acquisition has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Exagen and MedTech Acquisition, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Exagen | 0 | 1 | 3 | 0 | 2.75 |
| MedTech Acquisition | 0 | 0 | 0 | 0 | N/A |
Exagen currently has a consensus target price of $6.50, indicating a potential upside of 109.00%. Given Exagen’s higher probable upside, research analysts clearly believe Exagen is more favorable than MedTech Acquisition.
About Exagen
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
About MedTech Acquisition
MedTech Acquisition Corporation does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare sector in the United States. The company was incorporated in 2020 and is based in Greenwich, Connecticut. MedTech Acquisition Corporation operates as a subsidiary of Medtech Acquisition Sponsor LLC.
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.
